Harrisburg, PA, United States
Harrisburg, PA, United States

Time filter

Source Type

News Article | February 15, 2017
Site: www.prweb.com

Dr. Thomas E. Young, Owner and Medical Director of Young Medical Spa® is excited to announce a new service: SculpSure® for reducing excess fat on areas of the body that are resistant to diet and exercise. An FDA-cleared body contouring treatment, SculpSure can reduce unwanted fat on the abdomen, love handles, and flanks, using state-of-the-art technology to provide patients with a slimmer, trimmer figure. Stubborn fat can negatively affect body contours for both women and men. This non-invasive, no-downtime treatment is capable of simultaneously treating multiple areas for an expedited treatment that takes just 25 minutes. For patients who maintain a healthy lifestyle, SculpSure results can be permanent. SculpSure uses targeted light to heat and disrupt fat cells without harming surrounding tissues. These fat cells are then absorbed and ultimately flushed naturally from the body. Initial results can become apparent as early as six weeks following treatments, and patients typically see final results within months. Patients can begin to see results after one SculpSure treatment, though additional treatments may be necessary to achieve desired results. Please visit YoungMedicalSpa.com to learn more about SculpSure treatments at Young Medical Spa. Center Valley area patients can also call 610-816-0077; Lansdale area residents can learn more about this new service by calling 215-660-4121. About Young Medical Spa in Center Valley and Lansdale Pennsylvania Dr. Thomas E. Young founded Young Medical Spa with the mission to provide the highest quality aesthetic treatments and services within the comfort of a relaxing, spa-like environment. At Young Medical Spa in the Lehigh Valley and Montgomery County regions, all patients are treated under the supervision of medical aesthetic experts to ensure that results match the team’s passion for aesthetic medicine. Dr. Young is a leader within the medical aesthetic industry, and shares his expertise by training other physicians with his advanced techniques and wealth of experience. At Young Medical Spa, Dr. Young works diligently to ensure that each patient is able to achieve their desired results within a state-of-the-art location and in the company of a friendly and welcoming staff. Young Medical Spa has two locations serving the Lehigh Valley and greater Philadelphia areas. Their Center Valley medical spa is convenient to Allentown, Bethlehem, and Easton. The Lansdale medical spa is located in Montgomery County outside of Philadelphia, serving King of Prussia and Lower Bucks County. Every patient is given the time and attention necessary to develop a unique treatment plan and foster a valuable relationship with the staff. Young Medical Spa is dedicated to patient care and comfort, maximizing results while ensuring the utmost safety. Young Medical Spa is conveniently located at 4025 West Hopewell Road in Center Valley, PA, and at 635 North Broad Street, Lansdale, PA. About Dr. Thomas E. Young Thomas E. Young, M.D. is the owner and medical director of Young Medical Spa® located in the Lehigh Valley and Lansdale, PA. Double board-certified by the American Board of Internal Medicine, he is a native of the Lehigh Valley, and has been practicing medicine in the Lehigh Valley and surrounding areas since completing his residency at the Harrisburg Hospital. He is an experienced cosmetic injector and specializes in multiple awake tumescent procedures and techniques, and began performing SmartLipo™ Laser Body Sculpting™ soon after approval by the FDA. Dr. Young has performed over 6,000 procedures to date, identifying him as the most experienced awake tumescent liposuction physician in the region. Dr. Young is consistently the first physician to introduce many advanced aesthetic procedures and technologies to the region including awake tumescent laser liposuction, natural breast augmentation, Brazilian butt lift, Cellulaze™ cellulite reduction, CoolSculpting®, EndyMed Skin Tightening, thread lifts, and stem cell procedures. He also trains other physicians across the country in awake tumescent liposuction & liposculpture procedures. Dr. Young received an International Award in the category of “Best Overall Body Make-Over (a combination of procedures)” at the inaugural THE Aesthetic Awards™ at THE Aesthetic Show™ in Las Vegas, NV. He also has been voted “Leading Aesthetic Physician – Botox, Laser & Cosmetic Enhancements” in the 2011, 2012, 2013, 2014, 2015 & 2016 “Who’s Who in Business” for the Lehigh Valley, and was twice voted “Best Aesthetic Physician” by Lehigh Valley Magazine’s “Best of the Valley” Readers Poll. Additionally, Young Medical Spa was voted “Best Medical Spa” in The Morning Call’s Readers’ Choice Awards in 2011, 2012, 2013, 2014 and 2015.


News Article | November 15, 2016
Site: www.prweb.com

Young Medical Spa® is proud to announce that it has been named a Diamond Crystal level CoolSculpting® provider. As one of the first practices in Eastern Pennsylvania to offer this innovative non-invasive fat reduction treatment, Young Medical Spa and its founder, Dr. Thomas E. Young, have set themselves apart in terms of their expertise and quality of care. The Diamond Crystal level is the highest possible distinction presented to providers of CoolSculpting, and only a small handful of practices nationwide have met its demanding standards. It is reserved for only the most successful practices, which perform thousands of CoolSculpting treatments each year and consistently provide top-of-the-line service to their patients. CoolSculpting is a non-surgical treatment that eliminates fat from troublesome areas of the body. Using cryolipolysis technology, fat cells on the abdomen, thighs, flanks, love handles, under the chin, and more are frozen, shrinking them so they can be naturally flushed from the body through the lymphatic system. CoolSculpting requires little to no downtime and patients can see their results a few weeks following treatment. As one of the premier body sculpting destinations in the Philadelphia area, Young Medical Spa also offers liposuction to meet a variety of needs when it comes to fat reduction. Laser Lipo can permanently remove fat on the abdomen, waist, love handles, arms, thighs, and many more. Dr. Young is renowned for his liposuction technique and was the first to offer SmartLipo® Laser Liposuction in the region. Young Medical Spa believes in providing patients with only the highest quality of care, and plans to continue their excellence in fat reduction treatments. With two accessible locations in Lansdale and Center Valley, Young Medical Spa is convenient to patients in the Philadelphia, Allentown, Bethlehem, and Easton areas. About Young Medical Spa in Lehigh Valley and Montgomery County Pennsylvania Dr. Thomas E. Young founded Young Medical Spa with the mission to provide the highest quality aesthetic treatments and services within the comfort of a relaxing, spa-like environment. At Young Medical Spa in Pennsylvania, all patients are treated under the supervision of medical aesthetic experts to ensure that results match the team’s passion for aesthetic medicine. Dr. Young is a leader within the medical aesthetic industry, and shares his expertise by training other physicians with his advanced techniques and wealth of experience. At Young Medical Spa, Dr. Young works diligently to ensure that each patient is able to achieve their desired results within a state-of-the-art location and in the company of a friendly and welcoming staff. Young Medical Spa has two locations serving the Lehigh Valley and greater Philadelphia areas. Their Center Valley medical spa is convenient to Allentown, Bethlehem, and Easton. The Lansdale medical spa is located in Montgomery County outside of Philadelphia, serving King of Prussia and Lower Bucks County. Every patient is given the time and attention necessary to develop a unique treatment plan and foster a valuable relationship with the staff. Young Medical Spa is dedicated to patient care and comfort, maximizing results while ensuring the utmost safety. Young Medical Spa is conveniently located at 4025 West Hopewell Road in Center Valley, PA, and at 635 North Broad Street, Lansdale, PA. Thomas E. Young, M.D. is the Owner and Medical Director of Young Medical Spa® located in the Lehigh Valley and Lansdale, PA. Double board-certified by the American Board of Internal Medicine, he is a native of the Lehigh Valley, and has been practicing medicine in the Lehigh Valley and surrounding areas since completing his residency at the Harrisburg Hospital. He is an experienced cosmetic injector and specializes in multiple awake tumescent procedures and techniques, and began performing SmartLipo™ Laser Body Sculpting™ soon after approval by the FDA. Dr. Young has performed over 6,000 procedures to date, identifying him as the most experienced awake tumescent liposuction physician in the region. Dr. Young is consistently the first physician to introduce many advanced aesthetic procedures and technologies to the region including awake tumescent laser liposuction, natural breast augmentation, Brazilian Butt Lift, Cellulaze™ cellulite reduction, CoolSculpting®, Kybella® injections for submittal fat, ThermiVa® vaginal rejuvenation, and stem cell procedures. He also trains other physicians across the country in awake tumescent liposuction & liposculpture procedures. Dr. Young received an International Award in the category of “Best Overall Body Make-Over (a combination of procedures)” at the inaugural THE Aesthetic Awards™ at THE Aesthetic Show™ in Las Vegas, NV. He also has been voted “Leading Aesthetic Physician – Botox, Laser & Cosmetic Enhancements” in the 2011, 2012, 2013, 2014 and 2015 “Who’s Who in Business” for the Lehigh Valley, and was twice voted “Best Aesthetic Physician” by Lehigh Valley Magazine’s “Best of the Valley” Readers Poll. Additionally, Young Medical Spa was voted “Best Medical Spa” in The Morning Call’s Readers’ Choice Awards in 2011, 2012, 2013, 2014 and 2015.


News Article | February 28, 2017
Site: www.prweb.com

Dr. Thomas E. Young, Owner and Medical Director of Young Medical Spa®, is excited to announce the addition of a new service: Bio-Identical Hormone Replacement Therapy for restoring hormonal balance and improving overall health and vitality. Suitable for both men and women, Bio-Identical Hormone Replacement Therapy may help correct hormonal imbalances that can result from aging, relieving such symptoms as depression, fatigue, migraines, low libido, urinary incontinence, lack of mental clarity, trouble sleeping, and more. A customizable treatment that is tailored to each patient’s exact needs, Bio-Identical Hormone Replacement Therapy at Young Medical Spa involves inserting tiny pellets beneath the skin that gradually release a steady stream of natural hormones over time. Patients can receive therapy for low testosterone, estrogen, or a combination of both hormones, as needed. In concert with Bio-Identical Hormone Replacement Therapy, Young Medical Spa clients have access to a complete line of nutraceuticals that promote thyroid, heart, liver, and brain health. The combination of nutraceuticals and Bio-Identical Hormone Replacement Therapy provides a natural approach for long-lasting results without the potential negative side effects of prescription medications and traditional synthetic hormone replacement therapy methods. Young Medical Spa offers Bio-Identical Hormone Replacement Therapy at both of its locations in Lansdale and Center Valley, convenient to patients in the greater Philadelphia and Lehigh Valley areas. Please visit youngmedicalspa.com to learn more about these treatments at Young Medical Spa. Center Valley patients can also call 610-816-0077; Lansdale residents can learn more about this new service by calling 215-660-4121. About Young Medical Spa in Center Valley and Lansdale Pennsylvania Dr. Thomas E. Young founded Young Medical Spa with the mission to provide the highest quality aesthetic treatments and services within the comfort of a relaxing, spa-like environment. At Young Medical Spa in the Lehigh Valley region, all patients are treated under the supervision of medical aesthetic experts to ensure that results match the team’s passion for aesthetic medicine. Dr. Young is a leader within the medical aesthetic industry, and shares his expertise by training other physicians with his advanced techniques and wealth of experience. At Young Medical Spa, Dr. Young works diligently to ensure that each patient is able to achieve their desired results within a state-of-the-art location and in the company of a friendly and welcoming staff. Services offered include Bio-identical hormone replacement therapy (BHRT), hand rejuvenation, intimate rejuvenation with ThermiVa®, P-Shot®, and O-Shot®. Patients can undergo facelifts, neck lifts, eyelid surgery, thread lifts, Kybella™, and PrecisionTX™ for facial contouring. Body sculpting and shaping treatments include SmartLipo Triplex™, CoolSculpting®, SculpSure®, Brazilian butt lift, natural breast augmentation, cellulite reduction, and the Young Diet Program. Botox®, Dysport®, and dermal fillers (Juvéderm®, Restylane®, Radiesse®, Belotero Balance®, and Voluma® are administered with clinical and aesthetic expertise. Young Medical Spa is a Brilliant Distinctions® participant and a Cynosure Center of Excellence. Additional services include Laser Hair Removal and skin rejuvenation (IPL photofacials, microneedling, skin tightening, laser skin resurfacing, stretch marks & scar revision, laser leg vein therapy, chemical peels, microdermabrasion, and clinical facials. Clients can also purchase from a suite of professional medical-grade skin care products. Young Medical Spa has two locations serving the Lehigh Valley and greater Philadelphia areas. Their Center Valley medical spa is convenient to Allentown, Bethlehem, and Easton. The Lansdale medical spa is located in Montgomery County outside of Philadelphia, serving King of Prussia and Lower Bucks County. Every patient is given the time and attention necessary to develop a unique treatment plan and foster a valuable relationship with the staff. Young Medical Spa is dedicated to patient care and comfort, maximizing results while ensuring the utmost safety. Young Medical Spa is conveniently located at 4025 West Hopewell Road in Center Valley, PA, and at 635 North Broad Street, Lansdale, PA. About Dr. Thomas Young Thomas E. Young, M.D. is the owner and medical director of Young Medical Spa® located in the Lehigh Valley and Lansdale, PA. Double board-certified by the American Board of Internal Medicine, he is a native of the Lehigh Valley, and has been practicing medicine in the Lehigh Valley and surrounding areas since completing his residency at the Harrisburg Hospital. He is double-board certified by the American Board of Internal Medicine in Internal Medicine and Geriatrics. Dr. Young is an experienced cosmetic injector and specializes in multiple awake tumescent procedures and techniques, and began performing SmartLipo™ Laser Body Sculpting™ soon after approval by the FDA. Dr. Young has performed well over 6,000 procedures to date, identifying him as the most experienced awake tumescent liposuction physician in the region. Dr. Young is consistently the first physician to introduce many advanced aesthetic procedures and technologies to the region including awake tumescent laser liposuction, natural breast augmentation, Brazilian butt lift, Cellulaze™ cellulite reduction, CoolSculpting®, SculpSure® and stem cell procedures. He also trains other physicians across the country in awake tumescent liposuction & liposculpture procedures. Dr. Young received an International Award in the category of “Best Overall Body Make-Over (a combination of procedures)” at the inaugural THE Aesthetic Awards™ at THE Aesthetic Show™ in Las Vegas, NV. He also has been voted “Leading Aesthetic Physician – Botox, Laser & Cosmetic Enhancements” in the 2011, 2012, 2013, 2014, 2015, and 2017 “Who’s Who in Business” for the Lehigh Valley, and was twice voted “Best Aesthetic Physician” by Lehigh Valley Magazine’s “Best of the Valley” Readers Poll. Additionally, Young Medical Spa was voted “Best Medical Spa” in The Morning Call’s Readers’ Choice Awards in 2011, 2012, 2013, 2014 and 2015.


Giugliano G.R.,Baystate Medical Center | Falcone M.W.,Providence Hospital | Mego D.,Arkansas Heart Hospital | Ebersole D.,Lakeland Regional Medial Center | And 6 more authors.
Cardiovascular Revascularization Medicine | Year: 2012

Purpose: The primary aim of this study was to prospectively evaluate the safety and efficacy of Excimer laser atherectomy as a primary treatment strategy in consecutively eligible patients presenting for percutaneous coronary intervention (PCI) of degenerated saphenous vein graft (SVG) lesions using a multicenter registry. Prior single-center experience suggested that laser atherectomy may decrease acute procedural complications during treatment of degenerated SVGs, including lesions not amenable to distal protection devices (DPDs). Methods and materials: The COronary graft Results following Atherectomy with Laser investigators enrolled 98 patients at 18 centers between June 23, 2003, and October 4, 2004, with greater than 50% stenosis of an SVG who presented for PCI due to angina pectoris or objective evidence of myocardial ischemia in a concordant myocardial distribution. Laser atherectomy was planned. Patients were excluded if the operator planned to utilize a DPD. Inclusion and exclusion criteria were aligned to those in the Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) trial. Results: The primary end point [30-day major adverse cardiac events (MACE)] occurred in 18/98 (18.4%) patients driven primarily by non-q-wave myocardial infarction. Major procedural complications included no reflow (. n=5) and major dissection (. n=1). No perforations occurred. Univariate predictors of 30-day MACE included lesion length, vessel angulation, plaque burden, SVG degeneracy score, number of laser pulses used, and larger-sized laser catheters. Conclusions: This study demonstrated that Excimer laser atherectomy of diseased SVGs is feasible with results comparable to the 30-day MACE in the control population from the SAFER trial. Whether the addition of laser to embolic protection devices is of any clinical utility remains to be tested in future studies. © 2012 Elsevier Inc.


Xu Y.-Y.,Peking Union Medical College | Buyantseva L.V.,Harrisburg Hospital | Agarwal N.S.,Cornell University | Olivieri K.,BioRx | And 2 more authors.
Clinical and Experimental Allergy | Year: 2013

Hereditary angioedema (HAE) is a rare disease characterized by recurrent, self-limiting episodes of swelling. New research and therapies have recently emerged and are now available; however, many physicians are not aware of the new developments in HAE. To update immunologists and other health care providers on new advances in HAE therapies, a PubMed, OVID and Google literature search were used to develop this manuscript. English language peer-reviewed angioedema articles were selected. High quality clinical trials were reviewed and summarized. Acute therapy in the past often consisted of symptom relief with narcotics, hydration and fresh frozen plasma (FFP). Androgens and FFP are frequently used despite multiple, significant side-effects. Newer therapies include C1-inhibitor - both human plasma derived and recombinant - as well as contact system modulators such as ecallantide and icatibant. These newer products can be used for treatment of acute attacks of HAE, and C1-inhibitors can also be used for prophylaxis. These disease-specific therapies have proven to work by placebo-controlled studies, have minimal adverse effects and can be utilized for the treatment of HAE. © 2013 Blackwell Publishing Ltd.


Hopkins L.N.,State University of New York at Buffalo | Myla S.V.,Hoag Hospital | Grube E.,Heart Center | Eles G.,Allegheny General Hospital | And 3 more authors.
EuroIntervention | Year: 2010

Aims: To investigate long-term outcomes achieved in high-surgical-risk patients and other clinically-relevant subgroups after carotid stenting with the NexStent and Filterwire EX/EZ devices. Methods and results: CABERNET, a prospective, multicentre, single-arm trial, enrolled 454 patients with extracranial internal carotid artery stenosis (symptomatic ≥50%, n=110; asymptomatic ≥60%, n=344). Early outcomes at one year have been reported. The 3-year Kaplan-Meier estimated event rates were: 7.2%, all stroke; 2.8%, major stroke; 4.8%, ipsilateral stroke; 17.7%, all death; 7.1%, myocardial infarction; 4.4%, target vessel revascularisation. Asymptomatic patients had significantly fewer major strokes than symptomatic patients (1.9% vs. 5.7%, P=0.03) and patients <80 years had significantly fewer ipsilateral strokes than those ≥80 years (3.2% vs. 10.7%, P=0.002). Stroke outcomes did not differ significantly between patients with anatomical risk factors compared with those with comorbid medical risk factors. Conclusions: Long-term outcomes achieved in high-surgical-risk patients with the NexStent and Filterwire EX/EZ devices are favourable. Outcomes may be better in asymptomatic patients or those younger than 80 years of age. These data will be helpful in estimating short-term risks of carotid stenting and balancing these risks against the long-term benefit of stroke prevention. © Europa Edition 2010. All rights reserved.


Harskamp R.E.,Duke University | Harskamp R.E.,University of Amsterdam | Bagai A.,University of Toronto | Halkos M.E.,Emory University | And 7 more authors.
American Heart Journal | Year: 2014

Background Hybrid coronary revascularization (HCR) represents a minimally invasive revascularization strategy in which the durability of the internal mammary artery to left anterior descending artery graft is combined with percutaneous coronary intervention to treat remaining lesions. We performed a systematic review and meta-analysis to compare clinical outcomes after HCR with conventional coronary artery bypass graft (CABG) surgery. Methods A comprehensive EMBASE and PUBMED search was performed for comparative studies evaluating in-hospital and 1-year death, myocardial infarction (MI), stroke, and repeat revascularization. Results Six observational studies (1 case control, 5 propensity adjusted) comprising 1,190 patients were included; 366 (30.8%) patients underwent HCR (185 staged and 181 concurrent), and 824 (69.2%) were treated with CABG (786 off-pump, 38 on-pump). Drug-eluting stents were used in 328 (89.6%) patients undergoing HCR. Hybrid coronary revascularization was associated with lower in-hospital need for blood transfusions, shorter length of stay, and faster return to work. No significant differences were found for the composite of death, MI, stroke, or repeat revascularization during hospitalization (odds ratio 0.63, 95% CI 0.25-1.58, P =.33) and at 1-year follow-up (odds ratio 0.49, 95% CI 0.20-1.24, P =.13). Comparisons of individual components showed no difference in all-cause mortality, MI, or stroke, but higher repeat revascularization among patients treated with HCR. Conclusions Hybrid coronary revascularization is associated with lower morbidity and similar in-hospital and 1-year major adverse cerebrovascular or cardiac events rates, but greater requirement for repeat revascularization compared with CABG. Further exploration of this strategy with adequately powered randomized trials is warranted. © 2014 Mosby, Inc.


Buyantseva L.V.,Harrisburg Hospital | Sardana N.,New York Presbyterian Hospital | Craig T.J.,Pennsylvania State University
Asian Pacific Journal of Allergy and Immunology | Year: 2012

Background: Hereditary Angioedema (HAE) is a rare disease characterized by recurrent, self-limiting episodes of swelling. New therapies have recently emerged and are now available; however, many physicians are not aware of the new medications, and their indications and contraindications. Objective: To update allergists and primary care physicians on new advances in HAE therapies. Data sources: A PubMed literature search was used to develop this manuscript. Study Selections: English language peer-reviewed angioedema articles were selected. High quality Phase II and III placebo-controlled clinical trials were reviewed and summarized. Results: Until 2008, therapy for HAE consisted of symptom relief with narcotics, hydration and fresh frozen plasma (FFP). Androgens and FFP are frequently used despite multiple, significant side effects. Newer therapies include C1-inhibitor - both human plasma derived and recombinant - as well as contact system modulators such as ecallantide and icatibant. All of these products can be used for treatment of acute attacks of HAE, and C1-inhibitors can also be used for prophylaxis. Conclusion: New, disease-specific therapies have recently emerged which are more efficacious, are proven to work by placebo-controlled studies, have minimal adverse effects, and can be utilized for the treatment of HAE.


Bachinsky W.B.,Harrisburg Hospital | Abdelsalam M.,Harrisburg Hospital | Boga G.,Harrisburg Hospital | Kiljanek L.,Harrisburg Hospital | And 2 more authors.
Journal of Interventional Cardiology | Year: 2012

Objective: We compared the outcomes of same sitting robotic-assisted hybrid coronary artery revascularization (HCR) with off-pump coronary artery bypass grafting (OPCABG) in similar patients with multivessel coronary artery disease. Background: HCR is a novel procedure in selected patients with multivessel coronary artery disease (CAD). Although there are some data on staged HCR, the data on same sitting HCR are limited. Methods: We conducted a prospective study comparing same sitting robotic-assisted HCR patients (n = 25) to a group of consecutive low to moderate risk OPCABG patients (n = 27) during the study period. HCR patients underwent robotic internal mammary artery takedown followed by OPCABG via minithoracotomy. After confirming graft patency, immediate percutaneous coronary intervention on the nonbypass arteries was performed. Comparative analyses were performed on in-hospital and 30 day outcomes. Results: The baseline characteristics were similar for both groups including the severity of CAD (Syntax score 33.5+/-8.2 vs. 34.9+/-8.2, P = 0.556). Overall MACE was similar between both groups; however, the HCR group showed improved hospital outcomes with lower need for postoperative transfusions (12% vs. 67%, P < 0.001), and shorter length of hospital stay (5.1+/-2.8 vs. 8.2+/-5.4 days, P < 0.01). Despite lower postoperative costs, the HCR group had higher overall hospital costs due to higher procedural costs ($33,984 +/-$4,806 vs. $27,816+/-$11,172, P < 0.0001). Propensity model analysis showed similar findings. The HCR group showed improved quality of life measures with shorter time to return to work (5.3+/-3.0 vs. 8.2+/- 4.6 weeks, P = 0.01). Conclusions: Same sitting HCR appears to be feasible and may offer superior outcomes to standard OPCABG, further studies are warranted. (J Interven Cardiol 2012;25:460-468) © 2012, Wiley Periodicals, Inc.


PubMed | Harrisburg Hospital
Type: | Journal: Case reports in infectious diseases | Year: 2014

Introduction. Aeromonas hydrophila is a gram negative bacillus that is native to aquatic environments that is increasingly reported in humans. This case is remarkable for A. hydrophila with an initial presentation of acute pancreatitis. Case Presentation. A 61-year-old male presented to the emergency department with nausea, vomiting, and abdominal pain for two days. His past medical history was significant for alcohol abuse. Initial laboratory examination showed an elevated white blood cell count, elevated lipase, and elevated liver function tests (LFT). Computer tomography (CT) showed peripancreatic inflammatory changes and retroperitoneal free fluid, suggestive of acute pancreatitis. The patient was treated with intravenous (IV) fluids and IV meropenem. After two days, the patient developed sepsis and respiratory failure and was intubated. Blood cultures were positive for Aeromonas hydrophila sensitive to ciprofloxacin which was added to his treatment. Additionally, it was discovered that this patient had recently vacationed in Florida where he consumed raw oysters. He was discharged home on the eighth day of the hospital admission. Conclusion. This is a rare case of A. hydrophila sepsis in an elderly patient with acute pancreatitis and a history of consumption of raw oysters. This case suggests that A. hydrophila can cause disseminated infection in immunocompetent individuals.

Loading Harrisburg Hospital collaborators
Loading Harrisburg Hospital collaborators